Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

References

• National cancer institute, cancer statistics. 2020. [accessed 10 February 2022]. https://www.Cancer.Gov/about-cancer/understanding/statistics
   Google Scholar
• Word health organisation, global cancer observatory, estimated number of new cases in 2020, worldwide, both sexes, all ages. 2022. [accessed 17 April 2022]. https://gco.Iarc.Fr/today/online-analysis-table?V=2020&mode=cancer&mode_population=continents&population=900&populations=&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5b%5d=0&ages_group%5b%5d=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1#collapse-by_country
   Google Scholar
• National cancer institute, cancer stat facts: Leukemia. 2022. [accessed 14 April 2022]. https://seer.Cancer.Gov/statfacts/html/leuks.Html
   Google Scholar
• American Cancer Society, leukemia in children. 2022. [access 17 April 2022]. https://www.Cancer.Org/cancer/leukemia-in-children.Html
   Google Scholar
• Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10(4):267–277.
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010;330(6009):1340–1344.
   PubMed Web of Science ®Google Scholar
• Jennings GT, Sechi S, Stevenson PM, Tuckey RC, Parmelee D, McAlister-Henn L. Cytosolic NADP (+)-dependent isocitrate dehydrogenase. Isolation of rat cDNA and study of tissue-specific and developmental expression of mRNA. J Biol Chem. 1994;269(37):23128–23134.
   PubMed Web of Science ®Google Scholar
• Dang L, Yen K, Attar EC. Idh mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, et al. Mutations of idh1 and idh2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24(5):1094–1096.
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339–344.
   PubMed Web of Science ®Google Scholar
• Hlavackova A, Vydra J, Chrastinova L, Kotlin R, Stikarova J, Suttnar J, Dyr JE. Targeted metabolomic profiling in acute myeloid leukemia with idh2r140 and idh2r172 mutations. Blood. 2018;132(1):1470–1470.
   PubMedGoogle Scholar
• Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJF, Bleeker FE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta. 2014;1846(2):326–341.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. Idh mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474–478.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Leukemic idh1 and idh2 mutations result in a hypermethylation phenotype, disrupt tet2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567.
   PubMed Web of Science ®Google Scholar
• Singla P, Luxami V, Paul K. Triazine as a promising scaffold for its versatile biological behavior. Eur J Med Chem. 2015;102(102):39–57.
   PubMedGoogle Scholar
• Chalermnon M, Cherdchom S, Sereemaspun A, Rojanathanes R, Khotavivattana T. Biguanide-based synthesis of 1,3,5-triazine derivatives with anticancer activity and 1,3,5-triazine incorporated calcium citrate nanoparticles. Molecules. 2021;26(4):1028–15.
   PubMed Web of Science ®Google Scholar
• Liu H, Long S, Rakesh KP, Zha G-F. Structure-activity relationships (SAR) of triazine derivatives: promising antimicrobial agents. Eur J Med Chem. 2020;185(185):111804–111814.
   PubMedGoogle Scholar
• Kubo T, Figg CA, Swartz JL, Brooks WLA, Sumerlin BS. Multifunctional homopolymers: postpolymerization modification via sequential nucleophilic aromatic substitution. Macromolecules. 2016;49(6):2077–2084.
   Web of Science ®Google Scholar
• Blotny G. Recent applications of 2, 4, 6-trichloro-1, 3, 5-triazine and its derivatives in organic synthesis. Tetrahedron. 2006;62(41):9507–9522.
   Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, et al. Targeted inhibition of mutant idh2 in leukemia cells induces cellular differentiation. Science. 2013;340(6132):622–626.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, David MD, Artin E, Straley K, Padyana A, Gross S, DeLaBarre B, Tobin E, et al. Ag-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic idh2 mutations. Cancer Discov. 2017;7(5):478–493.
   PubMed Web of Science ®Google Scholar
• Chen J, Yang J, Wei Q, Weng L, Wu F, Shi Y, Cheng X, Cai X, Hu C, Cao P. Identification of a selective inhibitor of idh2/r140q enzyme that induces cellular differentiation in leukemia cells. Cell Commun Signal. 2020;18(1):55.
   PubMed Web of Science ®Google Scholar
• Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, et al. Discovery of ag-120 (ivosidenib): a first-in-class mutant idh1 inhibitor for the treatment of idh1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305.
   PubMed Web of Science ®Google Scholar
• Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, Chen Y, Narayaraswamy R, Tong S, Wang F, et al. Vorasidenib (ag-881): a first-in-class, brain-penetrant dual inhibitor of mutant idh1 and 2 for treatment of glioma. ACS Med Chem Lett. 2020;11(2):101–107.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, III, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, et al. Vorasidenib, a dual inhibitor of mutant idh1/2, in recurrent or progressive glioma; results of a first-in-human phase i trial. Clin Cancer Res. 2021;27(16):4491–4499.
   PubMed Web of Science ®Google Scholar
• Doraiswamy A, Jayaprakash V, Kania M, Hahka-Kemppinen M, Yang Z, Rudinski M, Ravandi F. A phase 1, open-label, multicenter study of hmpl-306 in advanced hematological malignancies with isocitrate dehydrogenase (idh) mutations. Blood. 2021;138(1):4438–4438.
   Google Scholar
• Gao M, Zhu H, Fu L, Li Y, Bao X, Fu H, Quan H, Wang L, Lou L. Pharmacological characterization of tq05310, a potent inhibitor of isocitrate dehydrogenase 2 r140q and r172k mutants. Cancer Sci. 2019;110(10):3306–3314.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang Z, Li Y, Sun L, Peng D, Du D, Zhang X, Han L, Zhao L, Lu L, et al. Preclinical efficacy against acute myeloid leukaemia of sh1573, a novel mutant idh2 inhibitor approved for clinical trials in china. Acta Pharm Sin B. 2021;11(6):1526–1540.
   PubMed Web of Science ®Google Scholar
• Wang F, Li Z, Zhang T, Yan G, Hu M, Zhao L, Zhao Y, Chen Y. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2. Chem Biol Drug Des. 2018;91(6):1087–1093.
   PubMed Web of Science ®Google Scholar
• Che J, Huang F, Zhang M, Xu G, Qu B, Gao J, Chen B, Zhang J, Ying H, Hu Y, et al. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (idh2) displaying activity in acute myeloid leukemia cells. Eur J Med Chem. 2020;203(203):112491.
   PubMedGoogle Scholar
• Celgene corporation. Idhifa® (enasidenib) [package insert]. US food and drug administration website. 2020. [accessed 16 April 2022]. https://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2020/209606s004lbl.Pdf
   Google Scholar
• Eldeeb AH, Abo-Ashour MF, Angeli A, Bonardi A, Lasheen DS, Elrazaz EZ, Nocentini A, Gratteri P, Abdel-Aziz HA, Supuran CT. Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem. 2021;221(221):113486.
   PubMedGoogle Scholar
• Abdel-Mohsen HT, El Kerdawy AM, Omar MA, Petreni A, Allam RM, El Diwani HI, Supuran CT. Application of the dual-tail approach for the design and synthesis of novel thiopyrimidine–benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors. Eur J Med Chem. 2022;228(228):114004.
   PubMedGoogle Scholar
• Tawfik HO, Petreni A, Supuran CT, El-Hamamsy MH. Discovery of new carbonic anhydrase ix inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach. Eur J Med Chem. 2022;232(203):114190.
   PubMedGoogle Scholar
• Dinari M, Gharahi F, Asadi P. Synthesis, spectroscopic characterization, antimicrobial evaluation and molecular docking study of novel triazine-quinazolinone based hybrids. J Mol Struct . 2018;1156(1156):43–50.
   Google Scholar
• Zhu L, Luo K, Li K, Jin Y, Lin J. Design, synthesis and biological evaluation of 2-phenylquinoline-4-carboxamide derivatives as a new class of tubulin polymerization inhibitors. Bioorg Med Chem. 2017;25(21):5939–5951.
   PubMed Web of Science ®Google Scholar
• Xu Q, Dai B, Li Z, Xu L, Yang D, Gong P, Hou Y, Liu Y. Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as flt3 inhibitors for the treatment of acute myeloid leukemia. Bioorg Med Chem Lett. 2019;29(19):126630–126637.
   PubMed Web of Science ®Google Scholar
• Li XY, Li S, Lu GQ, Wang DP, Liu KI, Qian XH, Xue WH, Meng FH. Design, synthesis and biological evaluation of novel (e)-n-phenyl-4-(pyridine-acylhydrazone) benzamide derivatives as potential antitumor agents for the treatment of multiple myeloma (mm). Bioorg Chem. 2020;103(103):104189–10.
   PubMedGoogle Scholar
• Younis MH, Mohammed ER, Mohamed AR, Abdel-Aziz MM, Georgey HH, Abdel Gawad NM. Design, synthesis and anti-mycobacterium tuberculosis evaluation of new thiazolidin-4-one and thiazolo[3,2-a][1,3,5]triazine derivatives. Bioorg Chem. 2022;124(124):105807–105817.
   PubMedGoogle Scholar
• Feng LS, Su WQ, Cheng JB, Xiao T, Li HZ, Chen DA, Zhang Z-L. Benzimidazole hybrids as anticancer drugs: an updated review on anticancer properties, structure–activity relationship, and mechanisms of action (2019–2021). Arch Pharm. 2022;355(6):2200051–14.
   Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115.
   PubMed Web of Science ®Google Scholar
• Andersson M, SjöStrand J, Petersen A, Honarvar AKS, Karlsson J-O. Caspase and proteasome activity during staurosporin-induced apoptosis in lens epithelial cells. Invest Ophthalmol Vis Sci. 2000;(41(9):2623–2632.
   PubMed Web of Science ®Google Scholar
• Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol. 2003;15(6):725–731.
   PubMed Web of Science ®Google Scholar
• Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–1121.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464.
   PubMed Web of Science ®Google Scholar
• Solankee A, Kapadia K, Ana Ć, Soković M, Doytchinova I, Geronikaki A. Synthesis of some new s-triazine based chalcones and their derivatives as potent antimicrobial agents. Eur J Med Chem. 2010;45(2):510–518.
   PubMed Web of Science ®Google Scholar
• Polovkovych SV, Karkhut AI, Marintsova NG, Lesyk RB, Zimenkovsky BS, Novikov VP. Synthesis of new Schiff bases and polycyclic fused thiopyranothiazoles containing 4,6-dichloro-1,3,5-triazine moiety. J Heterocyclic Chem. 2013;50(6):1419–1424.
   Web of Science ®Google Scholar
• Motaghi MM, Beitollahi H, Tajik S, Hosseinzadeh R, Department of Chemistry, Kerman Branch, Islamic Azad University, Kerman, Iran. Nanostructure electrochemical sensor for voltammetric determination of vitamin c in the presence of vitamin b6: application to real sample analysis. Int J Electrochem Sci. 2016;11(9):7849–7860.
   Web of Science ®Google Scholar
• Peppel T, Köckerling M. Large 1,3,5-triazine-based ligands coordinating transition metal ions: syntheses and structures of the ligands and the ball shaped nanometer-scaled co complex [co(2,4-r-6-r′-1,3,5-triazine)2](br1.7(oh)0.3) · 4.8h2o {r = bis(2. Diphenylmethylene) Hydrazinyl; r′ = Piperidin-1-yl}. J Coordinat Chem. 2009;62(12):1902–1913.
   Web of Science ®Google Scholar
• Al-Rasheed HH, Sholkamy EN, Al Alshaikh M, Siddiqui MRH, Al-Obaidi AS, El-Faham A. Synthesis, characterization, and antimicrobial studies of novel series of 2,4-bis(hydrazino)-6-substituted-1,3,5-triazine and their Schiff base derivatives. J Chem . 2018;2018(2018):1–13.
   Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res. 1995;34(2):91–109.
   Web of Science ®Google Scholar
• Abdel-Aziz AAM, El-Azab AS, AlSaif NA, Obaidullah AJ, Al-Obaid AM, Al-Suwaidan IA. Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study. J Enzyme Inhib Med Chem . 2021;36(1):1520–1538.
   Web of Science ®Google Scholar
• Shoemaker RH. The nci60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813–823.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz AAM, El-Azab AS, Alanazi AM, Asiri YA, Al-Suwaidan IA, Maarouf AR, Ayyad RR, Shawer TZ. Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. J Enzyme Inhib Med Chem. 2016;31(5):796–809.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Ibrahim HS, Al-Ansary GH, Ghabbour HA, Elaasser MM, Ahmed HYA, Safwat NA. Novel [(3-indolylmethylene)hydrazono]indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation. J Enzyme Inhib Med Chem. 2018;33(1):686–700.
   PubMed Web of Science ®Google Scholar
• Burnette WN. Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein a. Anal Biochem. 1981;112(2):195–203.
   PubMed Web of Science ®Google Scholar